(Q38650669)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

title

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

main subject

acute myeloid leukemia

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Paul G Ekert

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

David C Huang

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Andrew W. Roberts

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

T-C Teh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

N-Y Nguyen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

D M Moujalled

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

D Segal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

G Pomilio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

S Rijal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

A Jabbour

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

K Lackovic

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

P Blombery

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

E Thompson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

G Lessene

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

S P Glaser

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

M A Guthridge

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

A H Wei

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

publication date

28 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

303-312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28751770%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

cites work

Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Programmed anuclear cell death delimits platelet life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

PUMA, a potent killer with or without p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

BH3-only proteins in apoptosis at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Genomic Classification and Prognosis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

Bcl-xL is an oncogenic driver in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

7 January 2021

inferred from DOI database lookup

FXa variants advance toward a therapy for bleeding

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

7 January 2021

inferred from DOI database lookup

Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.243

7 January 2021

inferred from DOI database lookup

Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.

1 reference

12 December 2020

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

1 reference

12 December 2020

Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo

1 reference

12 December 2020

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy

1 reference

12 December 2020

Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer

1 reference

12 December 2020